Bortezomib induces methylation changes in neuroblastoma cells that appear to play a significant role in resistance development to this compound.

ABSTRACT: The anticancer activity of bortezomib (BTZ) has been increasingly studied in a number of indications and promising results for the use of this treatment have been shown in neuroblastoma. As BTZ treatment is usually administered in cycles, the development of resistance and side effects in patients undergoing therapy with BTZ remains a major challenge for the clinical usage of this compound. Common resistance development also means that certain cells are able to survive BTZ treatment and bypass molecular mechanisms that render BTZ anticancer activity. We studied the methylome of neuroblastoma cells that survived BTZ treatment. Our results indicate that BTZ induces pronounced genome wide methylation changes in cells which recovered from the treatment. Functional analyses of identified methyla

SUBMITTER: Luczkowska K 

PROVIDER: S-EPMC8110815 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature